Pain Management

  • J. L. Villano
  • S. A. Grossman


Pain is defined as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage” [1]. Approximately 80% of patients with cancer will experience significant pain as a result of their disease and/or its treatment [2]. Optimal management of pain at all stages of the therapeutic pathway will reduce the suffering associated with cancer, enhancing quality of life and physiologic adaptation. Techniques for assessment of pain and evaluation of its underlying cause allow a precise diagnosis in most instances, allowing treatment to be tailored to individual needs. Pharmacologic and nonpharmacologic techniques described in this chapter are applicable to the management of both acute and chronic pain in cancer patients.


Neuropathic Pain Zoledronic Acid Nerve Block Cancer Pain Trigeminal Neuralgia 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Merskey H (1979) Pain terms: a list with definitions and notes on usage. Recommended by the IASP Subcommittee on Taxonomy. Pain 6:249–252CrossRefGoogle Scholar
  2. 2.
    Bonica JJ (1990) The management of pain, 2nd edn. Lea and Febiger, PhiladelphiaGoogle Scholar
  3. 3.
    Cleeland CS, Gonin R et al (1994) Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 330:592–596PubMedCrossRefGoogle Scholar
  4. 4.
    Grossman S (1993) Undertreatment of cancer pain: barriers and remedies. Support Care Cancer 1:74–78PubMedCrossRefGoogle Scholar
  5. 5.
    Von Roenn JH, Cleeland CS et al (1993) Physician attitudes and practice in cancer pain management. A survey from the Eastern Cooperative Oncology Group. Ann Intern Med 119:121–126Google Scholar
  6. 6.
    Marks RM, Sachar EJ (1973) Undertreatment of medical inpatients with narcotic analgesics. Ann Intern Med 78:173–181PubMedGoogle Scholar
  7. 7.
    Joint Commission on Accreditation of Healthcare Organizations (1999/2000) Comprehensive Accreditation Manual for Ambulatory Care (CAMAC): patient rights and organization ethics (1999). Available at:
  8. 8.
    Grossman SA, Benedetti C et al (2000) NCCN Practice guidelines for cancer pain version 2000. Oncology 14:135–150. Copyright National Comprehensive Cancer Network, Inc. To view the most recent version of the guideline, go online to Google Scholar
  9. 9.
    Vallerand AH (1997) Measurement issues in the comprehensive assessment of cancer pain. Semin Oncol Nurs 13:16–24PubMedCrossRefGoogle Scholar
  10. 10.
    Grossman S, Sheidler V et al (1991) Correlation of patient and caregiver ratings of cancer pain. J Pain Symptom Manage 6:53–57PubMedCrossRefGoogle Scholar
  11. 11.
    Rhodes DJ, Kashy RC et al (2001) Feasibility of quantitative pain assessment in outpatient oncology practice. J Clin Oncol 19:501–508PubMedGoogle Scholar
  12. 12.
    Jacox A, Carr DB, Payne R et al (1994) Management of cancer pain: clinical practice guideline, no 9. Agency for Health Care Policy and Research, U.S. Department of Health and Human Services, Public Health Service, RockvilleGoogle Scholar
  13. 13.
    Hagen NA, Elwood T et al (1997) Cancer pain emergencies: a protocol for management. J Pain Symptom Manage 14:45–50PubMedCrossRefGoogle Scholar
  14. 14.
    Foley KM (1985) The treatment of cancer pain. N Engl J Med 313:84–95PubMedCrossRefGoogle Scholar
  15. 15.
    Twycross RG, Fairfield S (1982) Pain in far-advanced cancer. Pain 14:303–310PubMedCrossRefGoogle Scholar
  16. 16.
    Portenoy RK, Lesage P (1999) Management of cancer pain. Lancet 353:1695–1700PubMedCrossRefGoogle Scholar
  17. 17.
    Mercadante S (1997) Malignant bone pain: pathophysiology and treatment. Pain 69:1–18PubMedCrossRefGoogle Scholar
  18. 18.
    Hortobagyi GN, Theriault RL et al (1996) Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. N Engl J Med 335:1785–1791PubMedCrossRefGoogle Scholar
  19. 19.
    Berenson JR, Lichtenstein A et al (1996) Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med 334:488–493PubMedCrossRefGoogle Scholar
  20. 20.
    Berenson JR, Rosen LS et al (2001) Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 91:1191–1200PubMedCrossRefGoogle Scholar
  21. 21.
    Weill A, Chiras J et al (1996) Spinal metastases: indications for and results of percutaneous injection of acrylic surgical cement. Radiology 199:241–247PubMedGoogle Scholar
  22. 22.
    Ettinger AB, Portenoy RK (1988) The use of corticosteroids in the treatment of symptoms associated with cancer. J Pain Symptom Manage 3:99–103PubMedCrossRefGoogle Scholar
  23. 23.
    Derogatis L, Morrow G et al (1983) The prevalence of psychiatric disorders among cancer patients. JAMA 249:751–757PubMedCrossRefGoogle Scholar
  24. 24.
    Massie MJ, Holland JC (1992) The cancer patient with pain: psychiatric complications and their management. J Pain Symptom Manage 7:99–109PubMedCrossRefGoogle Scholar
  25. 25.
    Loscalzo M (1996) Psychological approaches to the management of pain in patients with advanced cancer. Hematol Oncol Clin North Am 10:139–155PubMedCrossRefGoogle Scholar
  26. 26.
    Spiegel D, Moore R (1997) Imagery and hypnosis in the treatment of cancer patients. Oncology (Huntington) 11:1179–1189Google Scholar
  27. 27.
    World Health Organization (1990) Cancer pain relief. World Health Organization, GenevaGoogle Scholar
  28. 28.
    Malmberg AB, Rafferty MF, Yaksh TL (1994) Antinociceptive effect of spinally delivered prostaglandin E receptor antagonists in the formalin test on the rat. Neurosci Lett 173:193–196PubMedCrossRefGoogle Scholar
  29. 29.
    Levy MH (1996) Pharmacologic treatment of cancer pain. N Engl J Med 335:1124–1132PubMedCrossRefGoogle Scholar
  30. 30.
    Fitzgerald GA, Patrono C (2001) Drug therapy: the coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med 345:433–442PubMedCrossRefGoogle Scholar
  31. 31.
    Mercadante S, Sapio M et al (1997) Opioid-sparing effect of diclofenac in cancer pain. J Pain Symptom Manage 14:15–20PubMedCrossRefGoogle Scholar
  32. 32.
    Expert Working Group of the European Association for Palliative Care (1996) Morphine in cancer pain: modes of administration. BMJ 312:823–826CrossRefGoogle Scholar
  33. 33.
    Swanson G, Smith J et al (1989) Patient-controlled analgesia for chronic cancer pain in the ambulatory setting: a report of 117 patients. J Clin Oncol 7:1903–1908PubMedGoogle Scholar
  34. 34.
    Grossman S, Sheidler V (1987) An aid to prescribing narcotics for the relief of cancer pain. World Health Forum 8:525–529Google Scholar
  35. 35.
    De Stoutz ND, Bruera E et al (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10:378–384PubMedCrossRefGoogle Scholar
  36. 36.
    Payne R, Chandler S et al (1995) Guidelines for the clinical use of transdermal fentanyl. Anticancer Drugs 6 [Suppl 3]:50–53PubMedCrossRefGoogle Scholar
  37. 37.
    Bruera E, Pereira J et al (1996) Opioid rotation in patients with cancer pain. A retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 78:852–857PubMedCrossRefGoogle Scholar
  38. 38.
    Hagen N, Swanson R (1997) Strychnine-like multifocal myoclonus and seizures in extremely high-dose opioid administration: treatment strategies. J Pain Symptom Manage 14:51–58PubMedCrossRefGoogle Scholar
  39. 39.
    Portenoy RK (1996) Adjuvant analgesic agents. Hematol Oncol Clin North Am 10:103–119PubMedCrossRefGoogle Scholar
  40. 40.
    McQuay H, Carroll D et al (1995) Anticonvulsant drugs for management of pain: a systematic review. BMJ 311: 1047–1052PubMedCrossRefGoogle Scholar
  41. 41.
    Marples IL, Murray P (1999) Neuropathic pain. Lancet 354:953–954PubMedCrossRefGoogle Scholar
  42. 42.
    Thompson JW, Filshie J (1992) In: Doyle D, Hanks G, Mac-Donald N (eds) Transcutaneous electrical nerve stimulation and acupuncture in palliative care medicine. Oxford University Press, New YorkGoogle Scholar
  43. 43.
    Cherny NI, Arbit E et al (1996) Invasive techniques in the management of cancer pain. Hematol Oncol Clin North Am 10:121–137PubMedCrossRefGoogle Scholar
  44. 44.
    Kawamata M, Ishitani K et al (1996) Comparison between celiac plexus block and morphine treatment on quality of life in patients with pancreatic cancer pain. Pain 64: 597–602PubMedCrossRefGoogle Scholar
  45. 45.
    Lamacraft G, Cousins MJ (1997) Neural blockade in chronic and cancer pain. Int Anesthesiol Clin 35:131–153PubMedCrossRefGoogle Scholar
  46. 46.
    Leong MS, Calabrese JF et al (2001) Intraventricular administration of morphine and clonidine. Anesthesiology 94:1141–1143PubMedCrossRefGoogle Scholar
  47. 47.
    Ballantyne JC, Carr DB et al (1996) Comparative efficacy of epidural, subarachnoid, and intracerebroventricular opioids in patients with pain due to cancer. Reg Anesth 21: 542–556PubMedGoogle Scholar
  48. 48.
    Gagliese L, Melzack R (1997) Chronic pain in elderly people. Pain 70:3–14PubMedCrossRefGoogle Scholar
  49. 49.
    Passik SD, Portenoy RK (1998) Substance abuse issues in palliative care. In: Berger A, Portenoy RK, Weissman DE (eds) Principles and practice of supportive oncology. Lippincott-Raven, PhiladelphiaGoogle Scholar
  50. 50.
    Grossman SA, Gregory RE (1994) In: Kirkwood JM, Lotze MT, Yasko JM (eds) Current cancer therapeutics, 1st edn. Current Medicine, PhiladelphiaGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2003

Authors and Affiliations

  • J. L. Villano
  • S. A. Grossman

There are no affiliations available

Personalised recommendations